TY  - GEN
AU  - Waldschmidt,Johannes M
AU  - Keller,Alexander
AU  - Ihorst,Gabriele
AU  - Grishina,Olga
AU  - Müller,Stefan
AU  - Wider,Dagmar
AU  - Frey,Anna V
AU  - King,Kristina
AU  - Simon,Roman
AU  - May,Annette
AU  - Tassone,Pierfrancesco
AU  - Duyster,Justus
AU  - Jung,Manfred
AU  - Raje,Noopur
AU  - Wäsch,Ralph
AU  - Engelhardt,Monika
TI  - Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
SN  - 1592-8721
PY  - 2019///1008
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Bortezomib
KW  - Dexamethasone
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Prospective Studies
KW  - Survival Rate
KW  - Vorinostat
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3324/haematol.2018.189969
ER  -